Consultation outcome

Classification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray

This consultation has concluded

Download the full outcome

Detail of outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate) from a pharmacy (P) medicine to a general sales list medicine (GSL).

See the public assessment report for more information.

Feedback received

Responses to ARM 83: request to reclassify Pirinase Hayfever Relief for Adults 0.05% Nasal Spray

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of feedback received

A total of 11 responses were received, of which 4 were in favour, 4 were not in favour, and 3 were responses with no comment. 1 of the responses was confidential.

Original consultation

This consultation ran from to

Summary

This consultation (ARM83) welcomes views on proposals to classify Pirinase Hayfever Relief for Adults 0.05% Nasal Spray as a general sales list (GSL) product in the UK.

This consultation was held on another website

Consultation description

Consultation ARM 83 seeks your views on the Pharmacy (P) to General Sales List (GSL) reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate).